Over 95% of Biotech IPOs choose NASDAQ. So why is Protalix (PLX) still on NYSE Markets?
Most if not all the top biotechs trade on NASDAQ. And over 95% of biotech IPOs choose NASDAQ. PLX needs to get off NYSE Markets and move to NASDAQ. Biotech IPO market has been active over the last two years.